PL2934593T3 - Kompozycja kabazytakselu - Google Patents

Kompozycja kabazytakselu

Info

Publication number
PL2934593T3
PL2934593T3 PL13874815T PL13874815T PL2934593T3 PL 2934593 T3 PL2934593 T3 PL 2934593T3 PL 13874815 T PL13874815 T PL 13874815T PL 13874815 T PL13874815 T PL 13874815T PL 2934593 T3 PL2934593 T3 PL 2934593T3
Authority
PL
Poland
Prior art keywords
cabazitaxel composition
cabazitaxel
composition
Prior art date
Application number
PL13874815T
Other languages
English (en)
Polish (pl)
Inventor
Valery Alakhov
Grzegorz Pietrzynski
Kishore Patel
Original Assignee
Softkemo Pharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Softkemo Pharma Corp. filed Critical Softkemo Pharma Corp.
Publication of PL2934593T3 publication Critical patent/PL2934593T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13874815T 2012-12-24 2013-12-23 Kompozycja kabazytakselu PL2934593T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261848172P 2012-12-24 2012-12-24
EP13874815.7A EP2934593B1 (en) 2012-12-24 2013-12-23 Cabazitaxel composition
PCT/IB2013/003255 WO2014122498A2 (en) 2012-12-24 2013-12-23 Cabazitaxel composition

Publications (1)

Publication Number Publication Date
PL2934593T3 true PL2934593T3 (pl) 2020-05-18

Family

ID=51300216

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13874815T PL2934593T3 (pl) 2012-12-24 2013-12-23 Kompozycja kabazytakselu

Country Status (16)

Country Link
US (1) US9919053B2 (OSRAM)
EP (1) EP2934593B1 (OSRAM)
JP (1) JP6498610B2 (OSRAM)
KR (1) KR102161866B1 (OSRAM)
CN (1) CN105142671B (OSRAM)
AU (1) AU2013377404B2 (OSRAM)
BR (1) BR112015015202B8 (OSRAM)
CA (1) CA2900508C (OSRAM)
DK (1) DK2934593T3 (OSRAM)
ES (1) ES2771423T3 (OSRAM)
HU (1) HUE048505T2 (OSRAM)
MX (1) MX371067B (OSRAM)
PL (1) PL2934593T3 (OSRAM)
PT (1) PT2934593T (OSRAM)
RU (1) RU2678772C2 (OSRAM)
WO (1) WO2014122498A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109731A1 (en) * 2016-12-16 2018-06-21 Orbicular Pharmaceutical Technologies Private Limited Pharmaceutical compositions of taxane and its derivatives
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技(广州)有限公司 一种注射用卡巴他赛组合物及其制备方法
EP3827822B1 (en) * 2018-07-25 2024-11-06 Bika Biotechnology (Guangzhou) Co., Ltd. Docetaxel composition for injection and preparation method therefor
AU2021342298A1 (en) * 2020-09-14 2023-05-18 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463687A1 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
WO2005035088A2 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
WO2005042584A2 (en) * 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013024495A1 (en) 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel

Also Published As

Publication number Publication date
JP6498610B2 (ja) 2019-04-10
BR112015015202A2 (pt) 2017-07-11
WO2014122498A2 (en) 2014-08-14
RU2678772C2 (ru) 2019-02-01
WO2014122498A3 (en) 2014-12-04
ES2771423T3 (es) 2020-07-06
MX2015008225A (es) 2016-07-20
CN105142671B (zh) 2018-09-14
KR102161866B1 (ko) 2020-10-05
CA2900508A1 (en) 2014-08-14
JP2016508138A (ja) 2016-03-17
US20150328321A1 (en) 2015-11-19
US9919053B2 (en) 2018-03-20
PT2934593T (pt) 2020-03-09
CA2900508C (en) 2021-04-13
EP2934593A4 (en) 2016-08-10
HUE048505T2 (hu) 2020-07-28
AU2013377404A1 (en) 2015-07-30
MX371067B (es) 2020-01-15
AU2013377404B2 (en) 2018-08-23
EP2934593B1 (en) 2020-02-05
KR20150127035A (ko) 2015-11-16
BR112015015202B1 (pt) 2021-12-21
CN105142671A (zh) 2015-12-09
RU2015130495A (ru) 2017-01-27
DK2934593T3 (da) 2020-02-17
EP2934593A2 (en) 2015-10-28
BR112015015202B8 (pt) 2022-02-15
AU2013377404A2 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
GB2506426B (en) Composition
PL2804487T3 (pl) Kompozycja
ZA201500519B (en) Composition
GB2498803B (en) Composition
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB201209244D0 (en) Compositions
GB2508825B (en) Composition
EP2867307A4 (en) COMPOSITION CONTAINING SILVER
GB201206035D0 (en) Composition
HRP20190326T1 (hr) Pripravak
PT2934593T (pt) Composição de cabazitaxel
ZA201407419B (en) Composition
IL236357A0 (en) The composition of misoprostol
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201218195D0 (en) Composition
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
GB201219383D0 (en) Composition
SG11201405751TA (en) Composition
GB201223526D0 (en) Composition
GB201223224D0 (en) Composition
GB201221334D0 (en) Composition
GB201220838D0 (en) Composition